A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC

Trial Details

NCT ID
NCT07135102
Phase
PHASE1
Sponsor
Xiaorong Sun
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 225Ac-PSMA-XT
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • have the ability to understand and sign an approved informed consent form (ICF).
  • \>= 18 years old.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • have a life expectancy \>6 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →